G. Coukos

Discipline

Histoire, Philosophie et Sociologie des sciences (9) Psychologie (4) Economies et finances (2) Sciences de l'information et de la communication (1)

Type de document

Articles (97) Recensions (20)

Co-auteur

Date

Source

Mot-clé

Cancer (58) cancer (57) Cancer (57) Immunotherapy (42) Immunotherapy (42) Cells (40) Tumors (36) Human beings (35) Patients (34) Tumors (34) Patients (34) T cells (32) Treatment (29) Therapeutics (25) Mice (25) Lymphocytes (23) thérapie (22) Use (21) spectacle (19) analyse (19) Analysis (19) roman (19) Expression (18) immunité (17) Immunity (17) Peptides (16) Molecules (15) puits (14) abords (agglomération) (14) Animals (14)

Documents écrit par G. Coukos (97) | parle de G. Coukos (0)

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
S. Anchisi et al. (31 déc. 2023)
Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8+ T cell exhaustion.
L. Tillé et al.
Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes.
J. Racle et al. (13 juin 2023)
The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer.
A.I. Kraemer et al.
Towards next-generation TIL therapy: TILs enriched in neoepitope-specific T cells.
M. Arnaud et al.
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap.
E. Ghisoni et al.
Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
U.F. Röhrig et al.
Low-dose irradiation for reversing immunotherapy resistance: how to translate?
M. Ochoa-de-Olza et al.
Deciphering the landscape of phosphorylated HLA-II ligands.
M. Solleder et al. (20 mai 2022)
Sensitive identification of neoantigens and cognate TCRs in human solid tumors.
M. Arnaud et al.
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
M. Ochoa-de-Olza et al.
A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors.
J.K. Fierle et al. (21 janv. 2022)
TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.
E.I. Matthaiou et al. (2022)
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
F.G. Herrera et al.
Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope.
H. Ebrahimi-Nik et al. (5 nov. 2021)
Microfluidic Device for Droplet Pairing by Combining Droplet Railing and Floating Trap Arrays.
M. Duchamp et al. (6 sept. 2021)
Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1.
J.K. Fierle et al. (17 août 2021)
Imaging angiogenesis in atherosclerosis in large arteries with 68Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease.
M. Dietz et al. (14 août 2021)
Interpretation of T cell states from single-cell transcriptomics data using reference atlases.
M. Andreatta et al. (20 mai 2021)
Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
J.L. Tanyi et al. (4 mai 2021)
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
J.L. Tanyi et al. (15 mars 2021)
Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab.
W.A. Mampuya et al.
Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
U.F. Röhrig et al. (25 févr. 2021)
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting.
J. Schmidt et al. (16 févr. 2021)
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
E. Lanitis et al. (1 févr. 2021)

next